| 规格： | 5mg | 产品价格： | 370 |
|---|
| 规格： | 25mg | 产品价格： | 1020 |
|---|
| 规格： | 100mg | 产品价格： | 2800 |
|---|
Catalog Number GC10165
Molecular Formula C24H29FN6O5
Relative Molecular Mass 500.52
CAS Registry Number 915769-50-5
Formulation A solid
Purity ≥98%
Storage Store at -20°C
SMILES FC1=C(C(N)=C(C2=O)C3=NC4=C(N3)C=C(N5CCN(C)CC5)C=C4)C(N2)=CC=C1.CC(O)C(O)=O.O
产品描述
Description:IC50: ~10 nmol/L for FGFR1–3Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are observed in approximately 10% of breast cancers and are related to poor outcomes. Dovitinib (TKI258) is an oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).In vitro: Dovitinib decreased the concentrations of pFRS2 and pERK/MAPK in a dose-dependent manner in FGFR1 amplified and FGFR2 amplified cell lines. The IC50 for cell growth inhibition was 190 and 180 nmol/L in MDA-MB-134 and SUM52, respectively. Conversely, IC50 values were more than 2,000 nmol/L in the 11 breast cancer cell lines that had neither FGFR1 nor FGFR2 amplification [1]. In vivo: In vivo model (HBCx-2 breast cancer primary xenograft, with 8 FGFR1 gene copies), dovitinib prevented tumor growth at the 30 mg/kg dose and caused tumor regression at the 50 mg/kg dose. Similarly, dovitinib caused tumor regression in HBCx-3 xenografts when administered at a dose of 40 mg/kg daily until day 35 [1]. Clinical trial: Eighty-one patients were enrolled in the trial. Unconfirmed response or stable disease for over 6 months was observed in 5 and 1 patient(s) with FGFR1-amplified/HR-positive and FGFR1-nonamplified/HR-positive breast cancer. When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway–amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients that did not present with FGF pathway–amplified breast cancer [1].Reference:[1] André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013 Jul 1;19(13):3693-702.
更多产品信息，请点击：https://www.glpbio.cn/search.php?catalog=GC10165原装进口,Dovitinib (TKI258) Lactate,美国GlpBio品Pai大包装更优惠!
美国Glpbio是一家领先的小分子YZ剂、激活剂、化合物库、多肽和实验室试剂的供应商。公司经营范围广泛，产品涉及癌症、免疫学、神经科学、细胞凋亡、表观遗传学等20多个不同研究领域，拥有10000多种产品。总部位于美国加利福尼亚，营销网点遍及法国、德国、加拿大、日本、澳大利亚、新加坡、以色列等20多个国家地区，竭诚为各国的科研工作者提供优质的产品和专业的服务。
温馨提示：不可用于临床ZL。
